Offerings / Regulation CF / Cytonus Therapeutics, Inc.
Cytonus Therapeutics, Inc.
Regulation Crowdfunding offering on Wefunder · Form C filed October 27, 2026 · San Diego, California
PreferredRevenue over $1MCorporation, Delaware
Business summary pending extraction from the offering statement. The company is a corporation organized in Delaware on August 21, 2018, based in San Diego, CA, with 3 employees and $1,275,587 of revenue in its most recent fiscal year.
Offering terms
- Security
- Preferred Stock
- Target (minimum)
- $50,000.00
- Maximum
- $1,000,000.00target is 5.0% of maximum
- Price
- $12.04 per unit · 4,153 units at target
- Pricing method
- Dividing pre-money valuation $96,030,426 (or $80,000,000 for investors in the first $100,000), which valuation was determined by management, by number of shares outstanding on fully diluted basis.
- Deadline
- April 30, 2027
- Oversubscriptions
- Accepted
- Intermediary fee
- 7.9% of the offering amount upon a successful fundraise, and reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering.
- Intermediary equity
- No
- Co-issuer
- Cytonus Therapeutics II, a series of Wefunder SPV, LLC
Cytonus Therapeutics II EB, a series of Wefunder SPV, LLC
Financials as filed
| Item | Most recent FY | Prior FY |
|---|---|---|
| Revenue | $1,275,587 | $851,415 |
| Cost of goods sold | $0 | $0 |
| Net income (loss) | -$2,244,653 | -$3,377,990 |
| Total assets | $2,016,065 | $1,934,050 |
| Cash and equivalents | $581,452 | $54,247 |
| Accounts receivable | $865,146 | $651,694 |
| Short-term debt | $1,345,542 | $1,492,640 |
| Long-term debt | $2,652,877 | $185,051 |
| Taxes paid | $0 | $0 |
Two fiscal years as reported on the Form C cover sheet. 3 employees. Offered in 56 states.